Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical senior executive Mark Brosius reported open-market sales of company common stock. As SVP and Chief Manufacturing and Supply Chain Officer, he sold a total of 3,658 shares across three transactions on March 3, 4, and 5, 2026.
The sales were executed at weighted-average prices of about $488.10, $498.6804, and $495.20 per share, with detailed price ranges provided in the footnotes. After these transactions, he directly held 2,906 shares of Intuitive Surgical common stock. All sales took place under a Trading Plan that complies with SEC Rule 10b5‑1 and expires on February 14, 2027.
Mark Brosius reported sales of ISRG common stock under 10b5-1 plans. The filing lists multiple 10b5-1 sales including 03/04/2026 sales of 431 shares for $213,426.89 and 1,931 shares for $964,456.23, 03/03/2026 sales of 431 shares for $209,974.58 and 217 shares for $106,314.22, 12/15/2025 sale of 464 shares for $254,499.36, and 12/12/2025 sales of 4,500 shares for $2,463,120.00 and 312 shares for $170,776.32.
The filing also lists securities to be sold as Performance Stock Units (522, 02/28/2026) and Restricted Stock Units (1,192, 02/10/2026).
ISRG reports a sale notice by an insider and scheduled restricted stock unit dispositions. A 10b5-1 sale executed 02/18/2026 shows 647 common shares sold for $323,500. The filing lists restricted stock units to be sold: 1,163 with date 02/26/2026 and 7,205 with date 02/28/2026, with Morgan Stanley Smith Barney LLC as broker.
Intuitive Surgical VP Corporate Controller Fredrik Widman reported planned share sales and RSU vesting activity. He sold 249 shares of common stock on February 27, 2026 at $499.71 per share, and 118 shares on March 3, 2026 at $487.18 per share in open-market transactions under a Rule 10b5-1 trading plan that runs through May 21, 2026.
These sales followed the vesting of 468 restricted stock units on February 28, 2026, which converted into the same number of common shares. To cover statutory tax withholding on the vesting, 233 shares of common stock were disposed of at $503.51 per share. After these transactions, Widman directly held just over one thousand common shares.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported net insider sales of common stock through a trust. A trust associated with her sold 4,728 shares on March 3, 2026 at an average price of $487.18 per share, leaving 409 indirectly owned shares.
On March 2, 2026, a non-qualified stock option for 125 shares was exercised and converted into common stock at an exercise price of $208.90 per share, and those 125 shares were then sold the same day at $492.59 per share. The option position now shows zero shares remaining. The transactions were carried out under a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
Mark Brosius reported insider sales under 10b5-1 plans and listed planned dispositions of equity awards. The excerpt shows three 10b5-1 sales in December 2025: 4,500, 464, and 312 shares, with proceeds of $2,463,120.00, $254,499.36, and $170,776.32 respectively. It also lists 2,154 Restricted Stock Units dated 02/10/2026 and 1,173 Performance Stock Units dated 02/28/2026 as securities to be sold.
Notice of proposed resale under Rule 144 for ISRG securities. The filing lists recent transactions by Fredrik Widman: sale of 249 common shares on 02/27/2026 for $124,427.79 and sale of 133 common shares on 02/11/2026 for $65,829.68. The form also lists restricted common stock associated with an issuer entry dated 02/28/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 for ISRG reporting proposed sales of 505 restricted stock and 4,223 performance shares dated 02/28/2026. The filing lists multiple recent open-market sales by Myriam Curet McAdams, including 2,345 shares on 02/27/2026 ($1,171,819.95) and 421 shares on 02/11/2026 ($208,378.16).
Intuitive Surgical executive Iman Jeddi, SVP & GM da Vinci Platforms, reported the vesting and settlement of equity awards. Performance stock units granted in 2023 and restricted stock units granted in 2022 were converted into common shares, with portions of the resulting stock (311 and 4,155 shares at $503.51) withheld to cover tax obligations rather than sold in the open market. Following these transactions, Jeddi holds common stock directly and indirectly through a trust.
Intuitive Surgical director Gary S. Guthart reported multiple equity award transactions in company stock. On February 28, 2026, he exercised 26,334 performance stock units and 2,506 restricted stock units, which converted into an equal number of common shares at no exercise price.
To satisfy statutory tax withholding on these settlements, 1,243 shares and 13,059 shares of common stock were disposed of at $503.51 per share, described as share withholding rather than open-market selling. Following these transactions, Guthart continued to hold common stock directly and also indirectly through several trusts for family members.